Establishing a production line for nanoparticles for pharmaceutical applications

Construction of Nanoform’s GMP manufacturing plant rapidly progresses

Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has announced significant progress in the construction of its new 600m2 GMP manufacturing plant, located at Cultivator II in Viikki Life Science Park, Finland. These important advancements in the project will enable the plant to begin operations in 2019.

Recent building progress includes the completed construction of the office space and R&D area in January, both of which are now operational. The project schedule has been accelerated with the commencement of work on the cleanroom and GMP-compliant areas, which are expected to be completed by the end of the third quarter. The facility is now on track to be licensed by the Finnish Medicines Agency by the end of this year.

By finalizing construction, Nanoform will double its capacity to handle potent APIs and provide nanonized materials for clinical trials. The rapid expansion in facilities will expediate further international commercialization of Nanoform’s nanonization™ technology, with patients across the globe set to benefit from the accelerated development of more efficient therapies.

Edward Hæggström, CEO of Nanoform, said: “We are delighted by the excellent construction progress that has already been achieved this year. The GMP manufacturing facility will allow more of our partners to benefit from our best-in-class nanoparticle engineering technology.”

Nanoform Finland Limited is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization™ services. The company’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESSᵀᴹ) technology produces nanonized “designed-for-purpose” API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization™ technology provides novel opportunities in diverse value enhancing drug delivery applications.

Reference: www.nanoform.fi

Positive results of pre-clinical test on lung cancer nano development

GenePrex has obtained positive results from a pre-clinical test on lung cancer nano development. It contains a tumor suppressor gene encoded in a cholesterol nanoparticle.

Genprex announced that in collaboration with the Anderson University of Texas Center, it has been able to conduct a pre-test on its new nanoparticle and has achieved positive results. This drug, called encoprex, can be used to treat lung cancer.

In year 4, Genprex Corporation signed a partnership agreement with the Anderson Center to partner with the Center to develop a drug for cancer treatment. This drug uses a substance called TUSC1, a type of tumor suppressor. This active ingredient is a flagship product of Geneprex, which is combined with autoimmune methods.

Researchers have shown that TUSC1 is a tumor suppressor gene that has very few side effects and has less side effects than traditional lung cancer drugs.

The company puts the TUSC1 gene in a cholesterol nanoparticle and uses it as engineered material to target cancer cells. At the American Cancer Research Association meeting, researchers at the Anderson Center presented the results of the test in a poster entitled Development of an improved humanized patient-derived xenograft, Hu-PDX, mouse model for antitumor immune response in lung cancer.

In the poster, the researchers showed that the combination of the TUSC1 gene with another drug had a great effect on the treatment of lung cancer, which increased the survival rate of mice bearing cancer cells. These data indicate that this treatment can significantly reduce the growth of cancer tumors.

“This very sophisticated model brings us one step closer to using the immune system against cancer, which has been done successfully on animal models,” says Julian Pham, a company spokesman for Geneprex. “These results enable us to evaluate our hypotheses about how the immune system interacts with a tumor after the drug is injected into the body.”

Application of nano-antibiotics in the diagnosis and treatment of infectious diseases

Application Despite the fact that we live in an age of new and advanced technologies to unveil the underlying disease mechanisms and design new drugs, it is one of the biggest challenges worldwide in the treatment of infectious diseases. Many antibiotics have been used to inhibit the growth and kill germs, but the development of resistance and the appearance of side effects have severely restricted the use of these agents. However, nanoscale biological compounds have unique physico-chemical properties that have proven in recent years the efficacy of several classes of nanocarriers and antimicrobial (NP) nanoparticles for the treatment of infectious diseases. The use of nanoparticles as markers in molecular diagnostics instead of current markers has increased the sensitivity, selectivity and multidimensional capacity of identification. In this article, we review recent efforts by researchers to identify and treat infectious diseases using antimicrobial nanoparticles and drug nanocarriers. Biotics in the detection and treatment of infectious diseases.

Infectious diseases are caused by pathogenic factors such as viruses (HIV, hepatitis C and dengue fever), parasites (malaria, trypanosomes and leishmania), bacteria (tuberculosis and cholera) and fungi. Infectious microorganisms spread throughout the body after invasion by the circulatory system, then are eliminated by macrophages that are found in the main organisms of the body such as the liver, spleen and bone marrow. However, most microorganisms resist macrophages and lead to infectious diseases through one of the phagosome-escape mechanisms, preventing lysosome-phagosome fusion and resistance to oxidative and non-oxidative deletion. These diseases are also known as communicable diseases due to their ability to spread from one person to another (malaria and tuberculosis) and sometimes from one species to another (influenza). As infectious diseases cause millions of deaths worldwide, especially in developing countries, they pose a serious threat to human health.

In the early twentieth century, infectious diseases were the leading cause of death worldwide. The decrease in the prevalence of infectious diseases and the deaths from these diseases in the last century is due to the recognition of antimicrobial agents. The use of antibiotics began with the commercial production of penicillin in the late 1980s and was claimed to be a major breakthrough until the 1990s, until newer and more powerful antibiotics were introduced. Despite extensive research and extensive investment, along with the development of antimicrobial drugs, resistance to these agents has expanded. Increasing bacterial resistance has made use of the strongest antibiotics ineffective (Figure 1). Antibiotic-resistant bacteria were screened to overcome drug resistance by discovering newer antibiotics and modifying existing drugs chemically. However, resistance to antibiotics has reached a critical level today, and unfortunately there is no guarantee that the development of new antimicrobials will overcome the rapid and rapid spread of resistance in time. For example, drug-resistant infections are on the rise in hospitals and the community, posing a serious threat to human health. So challenging treatment of infectious diseases requires long-term solutions.

Biomaterials and their medicinal properties

The concept of DNA nanotubes was introduced early in the year by Nadrian Seeman, who has made remarkable advances in nano science and technology so far. The main characteristic of DNA nanotubes is their self-assembly and molecular detection. Synthetic one-dimensional nanotubes have a wide range of applications ranging from nano electronics to biomedical research. The nanotubes are also made of 2D and 3D. Nucleic acid nanoparticles are used for gene therapy – cancer. Peptide nanotubes are also widely used, which can be used as antibiotics, drug carriers for the manufacture of artificial bone, and so on.
Nano is not a special science but a cross between science – physics, chemistry and biology – engineering – materials, electronics and mechanics – and medicine – medicine – and so on. Nanotechnology is an interdisciplinary science. Nanotechnology research and development requires interdisciplinary collaboration. Significant advances in nanoscience and nanotechnology include the discovery of C60, carbon nanotubes, DNA nanotubes, peptide nanotubes, as well as protein and peptide-based nanomaterials. The C60 was discovered in the year 8 by Richard Smalley and Robert Curl and Sir Harry Kroto, and their nanoparticle properties can be attributed to the placement of the drugs in the baseball cage. Somio Iijima also discovered a new form of carbon nanotubes in Japan in year 5. The concept of DNA nanotubes was first developed by Nadine Seeman at the beginning of the year. In 2006, he collaborated with Erik Winfree to create two-dimensional DNA nanotubes. Subsequently, a report on 3D nanotubes made of DNA was published in year 6 by him. The prerequisite for the drug application of the prepared nanotubes is their stability, permeability, and drug delivery factors.